Ripretinib for treating advanced gastrointestinal stromal tumours after 3 or more kinase inhibitors (review of TA881) [ID6496]
In development
Reference number: GID-TA11676
Expected publication date: TBC
This appraisal will be paused at the request of the company until NICE has the power to apply the new cost-effectiveness threshold. NICE anticipates that its cost-effectiveness threshold will increase in April 2026 and we will provide a further update to stakeholders at that time. More information about changes to NICE’s cost-effectiveness thresholds can be found here: https://www.nice.org.uk/news/articles/changes-to-nice-s-cost-effectiveness-thresholds-confirmed